Parnax Lab Ltd
Incorporated in 1985, Parnax Lab Ltd manufactures and exports Pharmaceutical Formulations[1]
- Market Cap ₹ 124 Cr.
- Current Price ₹ 108
- High / Low ₹ 194 / 81.0
- Stock P/E 10.8
- Book Value ₹ 72.4
- Dividend Yield 0.00 %
- ROCE 13.8 %
- ROE 14.9 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
70 | 103 | 71 | 95 | 106 | 109 | 95 | 90 | 163 | 168 | 189 | 188 | |
62 | 91 | 61 | 82 | 95 | 99 | 89 | 80 | 140 | 145 | 165 | 161 | |
Operating Profit | 8 | 12 | 10 | 13 | 10 | 10 | 6 | 10 | 23 | 23 | 24 | 27 |
OPM % | 12% | 12% | 14% | 14% | 10% | 9% | 7% | 11% | 14% | 14% | 12% | 14% |
1 | 1 | 1 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 2 | |
Interest | 4 | 4 | 4 | 5 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
Depreciation | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 6 | 7 | 7 | 7 |
Profit before tax | 3 | 5 | 3 | 5 | 3 | 5 | -2 | -0 | 12 | 12 | 12 | 16 |
Tax % | 27% | 22% | 28% | 22% | 65% | 28% | 48% | 350% | 33% | 30% | 20% | 26% |
2 | 4 | 3 | 4 | 1 | 3 | -3 | -0 | 8 | 9 | 10 | 12 | |
EPS in Rs | 2.93 | 5.01 | 2.95 | 4.33 | 1.23 | 3.88 | -3.42 | -0.42 | 8.40 | 7.51 | 8.37 | 10.03 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 6% |
5 Years: | 15% |
3 Years: | 5% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 43% |
3 Years: | 12% |
TTM: | 20% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 44% |
3 Years: | 2% |
1 Year: | -7% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 14% |
3 Years: | 15% |
Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 11 | 11 | 11 |
Reserves | 12 | 17 | 19 | 23 | 24 | 27 | 24 | 24 | 38 | 51 | 60 | 72 |
33 | 41 | 42 | 39 | 37 | 42 | 51 | 59 | 69 | 55 | 81 | 70 | |
29 | 17 | 10 | 15 | 18 | 17 | 23 | 15 | 36 | 28 | 37 | 37 | |
Total Liabilities | 83 | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 189 | 190 |
36 | 36 | 38 | 47 | 44 | 51 | 58 | 60 | 72 | 77 | 89 | 117 | |
CWIP | 1 | 1 | 2 | 0 | 0 | 0 | 3 | 5 | 3 | 2 | 21 | 1 |
Investments | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
46 | 45 | 38 | 38 | 43 | 43 | 46 | 41 | 78 | 66 | 79 | 72 | |
Total Assets | 83 | 83 | 79 | 86 | 87 | 95 | 107 | 106 | 153 | 145 | 189 | 190 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0 | -0 | 3 | 16 | 13 | 9 | 9 | 6 | 9 | 21 | 16 | 32 | |
-6 | -4 | -6 | -10 | -5 | -11 | -13 | -7 | -16 | -10 | -32 | -16 | |
6 | 6 | 1 | -5 | -7 | 1 | 5 | 0 | 12 | -14 | 15 | -16 | |
Net Cash Flow | 0 | 1 | -2 | 0 | 1 | -1 | 0 | -0 | 4 | -3 | -1 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 130 | 84 | 100 | 72 | 65 | 64 | 88 | 68 | 85 | 61 | 63 | 60 |
Inventory Days | 143 | 38 | 64 | 50 | 45 | 52 | 76 | 80 | 73 | 79 | 94 | 98 |
Days Payable | 203 | 51 | 30 | 48 | 45 | 44 | 74 | 46 | 81 | 53 | 70 | 81 |
Cash Conversion Cycle | 71 | 71 | 134 | 74 | 64 | 72 | 90 | 102 | 77 | 86 | 87 | 77 |
Working Capital Days | 75 | 59 | 74 | 34 | 44 | 53 | 77 | 103 | 73 | 67 | 75 | 60 |
ROCE % | 15% | 16% | 11% | 14% | 11% | 12% | 3% | 6% | 17% | 15% | 13% | 14% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Secretarial Compliance Report for FY ended March 31, 2025 confirming regulatory adherence.
- Financial Results For The Quarter And Year Ended March 31, 2025. 27 May
-
Board Meeting Outcome for Audited Financials Results For The Quarter And Year Ended March 31, 2025.
27 May - Audited standalone and consolidated financial results for FY ended March 31, 2025 approved by board.
-
Board Meeting Intimation for Approval Of Audited Standalone And Consolidated IND- AS Compliant Financial Results For The Quarter (Q4) And Year Ended 31St March, 2025.
20 May - Board meeting on May 27 to approve FY25 Q4 audited financial results; trading window closed since April 1.
-
Announcement Under Regulation 30, W.R.T. Intimation Of Change In Email And Website Address Of Registrar And Transfer Agent (''RTA'') Of Parnax Lab Limited (''Company'').
21 Apr - Change in email and website address of Parnax Lab's Registrar and Transfer Agent.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
PLL is a part Naxpar Group and is a WHO-approved and EHS-compliant Company. It is into contract manufacturing of Liquid Orals, Capsules, Ointments, External Powders & Tablets with its manufacturing facility located
at Silvassa.